Importantly, linc01503 was elucidated to epigenetically suppress dual‐specificity phosphatase 5 (DUSP5) and cyclin‐dependent kinase inhibitor 1A (CDKN1A) expression through binding with EZH2 and LSD1 in GC. Here, LINC01503 is linked to gastric cancer.